ARCHIVES

FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds

This article is from The Cancer Letter archive.

Vol. 26 No. 12 | December 26, 2003

Download PDF Visit The Full Archive

Related Articles

FDA to refer false statements by regulated companies to SEC.

February 27, 2004

Three Genetics Pioneers Win Nobel Prize

October 11, 2002

Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described

July 25, 1975

Nexavar Improves PFS In Phase III Trial

January 25, 2013

Triple-Negative Breast Cancer Equally Aggressive in Whites

February 25, 2011

“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s

September 20, 1991